Regulation of the Release of Inflammatory Mediators From Lung Macrophages.
Sponsor: Boehringer Ingelheim
Listed as NCT00147017, this observational or N/A phase trial focuses on COPD and Chronic Bronchitis and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 14 times since 2001, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
-
Dec 2021 — Dec 2022 [monthly]
Completed
▶ Show 9 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jan 2020 — Nov 2020 [monthly]
Completed
-
Dec 2019 — Jan 2020 [monthly]
Completed
-
Jun 2018 — Dec 2019 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Jun 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Imperial College London
- Novartis
- Royal Brompton & Harefield NHS Foundation Trust
For direct contact, visit the study record on ClinicalTrials.gov .